Mumbai-generic major Cipla has yet again made a mockery of Indian patent law by launching a generic version of Roche patented anti-infection drug Valganciclovir. This is the second instance of Cipla mocking Indian patent after it deliberately launched generic copy of Roche patented anti-cancer drug Erlotinib. Though we are not sure how much impact this will make on availability of drugs to Indian patients but surely it will deteriorate India’s image in global IP scenario. What is more pathetic is India’s legal state-of-affairs which is slowly becoming hand-puppet and regularly been twisted by politicians and strong businesses for their self-business interest. Politicians often used language and regionalism for their political gain but continue to ignore national interest and security for better growth and war against terrorism. Cipla too have mastered targeting high-pricing of innovators’ for their business interests but continue to ignore building healthcare infrastructure. Even after 60 years of independence only margin section of society have access to medicines with most even struggling for food and shelter. Post 1970 Indian generic companies including Cipla made phenomenal growth (in absence of patent protection for pharmaceutical drug products) to thousand crore plus company but still Indian healthcare scenario is struggling for better infrastructure. Over the years, Cipla has proudly publicized to provide cheap AIDS medicines to African countries when back here in India their own people are dying of common disease like tuberculosis, cholera and malaria. What can be more shameful when home grown pharma companies are more concern in exporting AIDS and cancer drugs rather than reaching to rural areas of India to provide medicines for common diseases which make more horror news than AIDS?